SCHEMBL5060685

SCHEMBL5060685

CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(-c4cn[nH]c4)c3)cc2)n(-c2cccc(C#N)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.50
MAP3K7 O43318 1/20 0.48
MAPK13 O15264 1/20 0.45
MAPK12 P53778 1/20 0.45
MAPK11 Q15759 1/20 0.45
MAPK14 Q16539 1/20 0.45
KCNJ6 P48051 4/20 0.44
KCNJ5 P48544 4/20 0.44
KCNJ3 P48549 4/20 0.44
KDR P35968 7/20 0.42
FLT3 P36888 1/20 0.41
FLT1 P17948 1/20 0.41
ROCK2 O75116 1/20 0.40
ABL1 P00519 1/20 0.40
AXL P30530 1/20 0.40
RAF1 P04049 1/20 0.40
SRC P12931 1/20 0.40
SYK P43405 1/20 0.40
GSK3A P49840 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5056317 0.92 BRAF (0.50) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL5056289 0.91 MAPK14 (0.48) BRAFMAP3K7MAPK11MAPK14KDR
SCHEMBL5062000 0.89 MAP3K7 (0.61) BRAFMAP3K7MAPK13MAPK12MAPK11
SCHEMBL5054691 0.89 KCNJ6 (0.52) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL5055083 0.88 KDR (0.52) BRAFMAP3K7MAPK13MAPK12MAPK11
SCHEMBL5052361 0.85 BRAF (0.46) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL5060252 0.84 ABL1 (0.59) BRAFMAP3K7MAPK13MAPK12MAPK11
SCHEMBL5055072 0.84 MAPK14 (0.48) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL5054974 0.84 BRAF (0.49) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL5060263 0.83 BRAF (0.47) BRAFMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 BRAF 2/4885MAP3K7 22/4885MAPK13 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.